Alamar Biosciences Strengthens Leadership Team for Future Growth Phase

Alamar Biosciences Welcomes New Leadership

Alamar Biosciences, a pioneering company in precision proteomics aimed at the earliest possible disease detection, recently made major announcements regarding its executive leadership team. These strategic moves are designed to bolster the company’s momentum and commitment to operational excellence and innovation, propelling it into its next phase of growth.

Leadership Promotions and Appointments

On October 16, 2025, Alamar disclosed that Tod White has been promoted to president. Since joining the company, White has been instrumental in shaping its strategic direction, overseeing a myriad of functions including finance, human resources, investor relations, and business development. His new role recognizes not just his substantial contributions but also the confidence the board has in his leadership skills moving forward.

Yuling Luo, the founder and CEO of Alamar Biosciences, expressed immense faith in White’s capabilities, stating, "Tod has been a cornerstone of our leadership team. His ability to manage complexity and foster interdepartmental alignment has been critical to our success. This appointment reflects the board's trust in his vision and capacity to lead Alamar as we expand and enhance our impact."

To add further strength to its financial leadership, Alamar has announced the appointment of Justin McAnear as the new Chief Financial Officer. McAnear brings over 25 years of comprehensive operational and financial leadership across various industries. Notably, he was a key player in the 2019 IPO of 10x Genomics, where he served as CFO for over five years. His illustrious career also includes a significant stint as Vice President of Global Finance and Operations at Tesla, where he played a pivotal role in launching models X and 3.

Luo remarked on McAnear’s addition, saying, "Having Justin on board is an exciting development for Alamar. He brings a unique blend of strategic insights and operational discipline, complemented by a deep understanding of developing complex organizations. I'm looking forward to collaborating with him on continuing the growth and evolution of our company."

Synergistic Expertise

Both Tod White and Justin McAnear present complementary skill sets that are expected to enhance Alamar's ability to seize emerging opportunities within the healthcare landscape. Their combined expertise reaffirms the company’s enduring dedication to innovation, integrity, and top-tier performance as they work towards revolutionizing disease detection methods.

About Alamar Biosciences

Alamar Biosciences is a private life sciences company on a mission to innovate precision proteomics, facilitating early disease detection. Its proprietary NULISA™ platform and ARGO™ HT system operate seamlessly with the latest advancements in genomics, achieving single-digit attomolar detection sensitivity, outperforming existing protein detection technologies available in the market. For additional information, visit alamarbio.com.